{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:24Z","timestamp":1794047484101,"version":"4.8.0"},"reference-count":91,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are hematopoietic stem disorders with a risk of progression to an accelerated phase (AP) or blast phase (BP) that is influenced by clinical, pathological, cytogenetic, and molecular variables. Overall survival of patients with MPN-AP\/BP is limited with current treatment approaches, particularly in those patients who cannot receive an allogeneic hematopoietic stem cell transplant (allo-HCT). In addition, long-term survival with allo-HCT is predominantly seen in chronic-phase MPN, which suggests that the ideal time for intervention may be before the MPN evolves to AP\/BP. In this review we focus on the risk factors for progression to MPN-AP\/BP, identification of high-risk chronic-phase MPN, potential early-intervention strategies, and considerations around the timing of allo-HCT. We also summarize current survival outcomes of patients with MPN-AP\/BP, discuss the uncertainty around how to best gauge response to therapy, and outline clinical trial considerations for this population of patients. Lastly, we highlight future directions in the management of high-risk MPN.<\/jats:p>","DOI":"10.3324\/haematol.2023.283950","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T03:21:53Z","timestamp":1729740113000},"page":"828-839","source":"Crossref","is-referenced-by-count":21,"title":["Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Anand A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"73636","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"73637","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms Leukemia. 2022; 36(7):1703-1719."},{"key":"73638","doi-asserted-by":"crossref","unstructured":"Patel AA, Odenike O. SOHO state of the art updates and next questions | accelerated phase of MPN: what it is and what to do about it. Clin Lymphoma Myeloma Leuk. 2023; 23(5):303-309.","DOI":"10.1016\/j.clml.2023.01.011"},{"key":"73639","doi-asserted-by":"crossref","unstructured":"Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020; 136(1):61-70.","DOI":"10.1182\/blood.2019000943"},{"key":"73640","doi-asserted-by":"crossref","unstructured":"Odenike O. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2018; 132(22):2339-2350.","DOI":"10.1182\/blood-2018-03-785907"},{"key":"73641","doi-asserted-by":"crossref","unstructured":"Mudireddy M, Gangat N, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis. Blood Cancer J. 2018; 8(6):57.","DOI":"10.1038\/s41408-018-0095-2"},{"key":"73642","doi-asserted-by":"crossref","unstructured":"Masarova L, Bose P, Pemmaraju N. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020; 126(19):4322-4331.","DOI":"10.1002\/cncr.33094"},{"key":"73643","doi-asserted-by":"crossref","unstructured":"Mesa RA, Li C-Y, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005; 105(3):973-977.","DOI":"10.1182\/blood-2004-07-2864"},{"key":"73644","doi-asserted-by":"crossref","unstructured":"Tam CS, Nussenzveig RM, Popat U. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008; 112(5):1628-1637.","DOI":"10.1182\/blood-2008-02-138230"},{"key":"73645","doi-asserted-by":"crossref","unstructured":"Kennedy JA, Atenafu EG, Messner HA. Treatment outcomes following leukemic transformation in Philadelphianegative myeloproliferative neoplasms. Blood. 2013; 121(14):2725-2733.","DOI":"10.1182\/blood-2012-10-464248"},{"key":"73646","doi-asserted-by":"crossref","unstructured":"Patel AA, Yoon JJ, Johnston H. Outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era of myeloid therapies. Blood. 2022; 140(Supplement 1):6860-6862.","DOI":"10.1182\/blood-2022-157603"},{"key":"73647","doi-asserted-by":"crossref","unstructured":"Abdulkarim K, Girodon F, Johansson P. AML transformation in 56 patients with Ph-MPD in two well defined populations. Eur J Haematol. 2009; 82(2):106-111.","DOI":"10.1111\/j.1600-0609.2008.01163.x"},{"key":"73648","doi-asserted-by":"crossref","unstructured":"Rampal R, Ahn J, Abdel-Wahab O. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A. 2014; 111(50):E5401-410.","DOI":"10.1073\/pnas.1407792111"},{"key":"73649","doi-asserted-by":"crossref","unstructured":"Lasho TL, Mudireddy M, Finke CM. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018; 2(4):370-380.","DOI":"10.1182\/bloodadvances.2018015875"},{"key":"73650","doi-asserted-by":"crossref","unstructured":"Venton G, Courtier F, Charbonnier A. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms. Am J Hematol. 2018; 93(3):330-338.","DOI":"10.1002\/ajh.24973"},{"key":"73651","doi-asserted-by":"crossref","unstructured":"McNamara CJ, Panzarella T, Kennedy JA. The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Adv. 2018; 2(20):2658-2671.","DOI":"10.1182\/bloodadvances.2018021469"},{"key":"73652","doi-asserted-by":"crossref","unstructured":"Tremblay D, Feld J, Dougherty M. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. Leuk Res. 2020; 98:106456.","DOI":"10.1016\/j.leukres.2020.106456"},{"key":"73653","doi-asserted-by":"crossref","unstructured":"King AC, Weis TM, Derkach A. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Am J Hematol. 2022; 97(1):E7-E10.","DOI":"10.1002\/ajh.26381"},{"key":"73654","doi-asserted-by":"crossref","unstructured":"Gangat N, Guglielmelli P, Szuber N. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. Am J Hematol. 2021; 96(7):781-789.","DOI":"10.1002\/ajh.26186"},{"key":"73655","doi-asserted-by":"crossref","unstructured":"Masarova L, DiNardo CD, Bose P. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv. 2021; 5(8):2156-2164.","DOI":"10.1182\/bloodadvances.2020003934"},{"key":"73656","doi-asserted-by":"crossref","unstructured":"Kuusanm\u00e4ki H, Dufva O, V\u00e4h\u00e4-Koskela M. Erythroid\/ megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood. 2023; 141(13):1610-1625.","DOI":"10.1182\/blood.2021011094"},{"key":"73657","doi-asserted-by":"crossref","unstructured":"R\u00fccker FG, Schlenk RF, Bullinger L. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119(9):2114-2121.","DOI":"10.1182\/blood-2011-08-375758"},{"key":"73658","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Pratz KW, Wei AH. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res. 2022; 28(24):5272-5279.","DOI":"10.1158\/1078-0432.CCR-22-1183"},{"key":"73659","doi-asserted-by":"crossref","unstructured":"Badar T, Atallah EL, Shallis RM. comparable survival of treatment na\u00efve TP53 mutated acute myeloid leukemia treated with hypomethylating agent compared to hypomethylating agent plus venetoclax based therapy. Blood. 2023; 142(Supplement 1):592.","DOI":"10.1182\/blood-2023-184626"},{"key":"73660","doi-asserted-by":"crossref","unstructured":"Drummond MW, Gaskell C, Harrison C. Phazar: a phase Ib study to assess the safety and tolerability of ruxolitinib in combination with azacitidine in advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN [ISRCTN16783472]. Blood. 2020; 136(Supplement 1):2-3.","DOI":"10.1182\/blood-2020-138437"},{"key":"73661","doi-asserted-by":"crossref","unstructured":"Bose P, Verstovsek S, Cortes JE. A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020; 34(9):2489-2492.","DOI":"10.1038\/s41375-020-0778-0"},{"key":"73662","doi-asserted-by":"crossref","unstructured":"Mascarenhas JO, Rampal RK, Kosiorek HE. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020; 4(20):5246-5256.","DOI":"10.1182\/bloodadvances.2020002119"},{"key":"73663","doi-asserted-by":"crossref","unstructured":"Patel AA, Cahill K, Charnot-Katsikas A. Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020; 190(1):e48-e51.","DOI":"10.1111\/bjh.16709"},{"key":"73664","doi-asserted-by":"crossref","unstructured":"Chifotides HT, Masarova L, Alfayez M. Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020; 4(21):5336-5342.","DOI":"10.1182\/bloodadvances.2020001528"},{"key":"73665","doi-asserted-by":"crossref","unstructured":"Gangat N, Ajufo H, Abdelmagid M. IDH1\/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: a multicentre experience. Br J Haematol. 2023; 203(3):e87-e92.","DOI":"10.1111\/bjh.19027"},{"key":"73666","doi-asserted-by":"crossref","unstructured":"Patel AA, Odenike O. Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):440-449.","DOI":"10.1182\/hematology.2020000129"},{"key":"73667","doi-asserted-by":"crossref","unstructured":"Gangat N, Caramazza D, Vaidya R. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011; 29(4):392-397.","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"73668","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Lasho TL, Rotunno G. MIPSS70: Mutation-enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018; 36(4):310-318.","DOI":"10.1200\/JCO.2017.76.4886"},{"key":"73669","doi-asserted-by":"crossref","unstructured":"Loscocco GG, Rotunno G, Mannelli F. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis. Am J Hematol. 2024; 99(1):68-78.","DOI":"10.1002\/ajh.27136"},{"key":"73670","doi-asserted-by":"crossref","unstructured":"Stein BL, Martin K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Blood. 2019; 134(22):1902-1911.","DOI":"10.1182\/blood.2019001318"},{"key":"73671","doi-asserted-by":"crossref","unstructured":"Luque Paz D, Jouanneau-Courville R, Riou J. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020; 4(19):4887-4897.","DOI":"10.1182\/bloodadvances.2020002271"},{"key":"73672","doi-asserted-by":"crossref","unstructured":"Harrison CN, Nangalia J, Boucher R. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023; 41(19):3534-3544.","DOI":"10.1200\/JCO.22.01935"},{"key":"73673","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Mora B, Gesullo F. JAK2V617F molecular response to ruxolitinib in patients with PV and ET is associated with lower risk of progression to secondary myelofibrosis. Blood. 2022; 140(Supplement 1):1788-1789.","DOI":"10.1182\/blood-2022-156781"},{"key":"73674","doi-asserted-by":"crossref","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Manshouri T. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009; 27(32):5418-5424.","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"73675","doi-asserted-by":"crossref","unstructured":"Huang B-T, Zeng Q-C, Zhao W-H, Li B-S, Chen R-L. Interferon a-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res. 2014; 38(10):1177-1183.","DOI":"10.1016\/j.leukres.2014.06.019"},{"key":"73676","doi-asserted-by":"crossref","unstructured":"Verger E, Cassinat B, Chauveau A. Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015; 126(24):2585-2591.","DOI":"10.1182\/blood-2015-07-659060"},{"key":"73677","doi-asserted-by":"crossref","unstructured":"Masarova L, Patel KP, Newberry KJ. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017; 4(4):e165-e175.","DOI":"10.1016\/S2352-3026(17)30030-3"},{"key":"73678","doi-asserted-by":"crossref","unstructured":"Bewersdorf JP, How J, Masarova L. Moving toward disease modification in polycythemia vera. Blood. 2023; 142(22):1859-1870.","DOI":"10.1182\/blood.2023021503"},{"key":"73679","doi-asserted-by":"crossref","unstructured":"Ramanathan G, Fleischman AG. The microenvironment in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021; 35(2):205-216.","DOI":"10.1016\/j.hoc.2020.11.003"},{"key":"73680","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29(10):1356-1363.","DOI":"10.1200\/JCO.2010.32.9490"},{"key":"73681","doi-asserted-by":"crossref","unstructured":"Rodriguez-Meira A, Norfo R, Wen S. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023; 55(9):1531-1541.","DOI":"10.1038\/s41588-023-01480-1"},{"key":"73682","doi-asserted-by":"crossref","unstructured":"Xie Z, Zeidan AM. CHIPing away the progression potential of CHIP: a new reality in the making. Blood Rev. 2023; 58:101001.","DOI":"10.1016\/j.blre.2022.101001"},{"key":"73683","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1):55.","DOI":"10.1186\/s13045-017-0417-z"},{"key":"73684","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N, Giorgino T, Scott BL. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015; 125(21):3347-3350.","DOI":"10.1182\/blood-2014-10-608315"},{"key":"73685","doi-asserted-by":"crossref","unstructured":"Gowin K, Ballen K, Ahn KW. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020; 4(9):1965-1973.","DOI":"10.1182\/bloodadvances.2019001084"},{"key":"73686","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019; 133(20):2233-2242.","DOI":"10.1182\/blood-2018-12-890889"},{"key":"73687","doi-asserted-by":"crossref","unstructured":"Tamari R, Rapaport F, Zhang N. Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019; 25(6):1142-1151.","DOI":"10.1016\/j.bbmt.2019.01.002"},{"key":"73688","doi-asserted-by":"crossref","unstructured":"Ali H, Aldoss I, Yang D. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen. Blood Adv. 2019; 3(1):83-95.","DOI":"10.1182\/bloodadvances.2018026658"},{"key":"73689","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N, Panagiota V, Badbaran A. Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017; 23(7):1095-1101.","DOI":"10.1016\/j.bbmt.2017.03.034"},{"key":"73690","doi-asserted-by":"crossref","unstructured":"Jain T, Tsai H-L, DeZern AE. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis. Transplant Cell Ther. 2022; 28(5):259.e1-259.e11.","DOI":"10.1016\/j.jtct.2022.02.004"},{"key":"73691","doi-asserted-by":"crossref","unstructured":"Stevens EA, Jenkins IC, Beppu LW. Targeted sequencing improves DIPSS-plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation. Biol Blood Marrow Transplant. 2020; 26(7):1371-1374.","DOI":"10.1016\/j.bbmt.2020.03.007"},{"key":"73692","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Badbaran A, Salit RB. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023; 141(23):2901-2911.","DOI":"10.1182\/blood.2023019630"},{"key":"73693","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Wolschke C, Salit RB. Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. Blood Adv. 2022; 6(4):1222-1231.","DOI":"10.1182\/bloodadvances.2021006827"},{"key":"73694","doi-asserted-by":"crossref","unstructured":"Gupta V, Kennedy JA, Capo-Chichi J-M. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020; 4(21):5562-5573.","DOI":"10.1182\/bloodadvances.2020002727"},{"key":"73695","doi-asserted-by":"crossref","unstructured":"Shah MV, Saliba RM, Varma A. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021; 193(5):1004-1008.","DOI":"10.1111\/bjh.17423"},{"key":"73696","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"73697","unstructured":"Zeidan AM, Platzbecker U, Bewersdorf JP. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood. 2023; 141(17):2047-2061."},{"key":"73698","doi-asserted-by":"crossref","unstructured":"Mascarenhas J, Heaney ML, Najfeld V. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012; 36(12):1500-1504.","DOI":"10.1016\/j.leukres.2012.08.013"},{"key":"73699","doi-asserted-by":"crossref","unstructured":"Gupta V, Kim S, Hu Z-H. Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS. Blood Adv. 2020; 4(19):4748-4757.","DOI":"10.1182\/bloodadvances.2020002621"},{"key":"73700","doi-asserted-by":"crossref","unstructured":"Wang X, Prakash S, Lu M. Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. J Clin Invest. 2012; 122(11):3888-3899.","DOI":"10.1172\/JCI64397"},{"key":"73701","doi-asserted-by":"crossref","unstructured":"Kremyanskaya M, Mascarenhas J, Rampal R, Hoffman R. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol. 2014; 167(1):144-146.","DOI":"10.1111\/bjh.12948"},{"key":"73702","doi-asserted-by":"crossref","unstructured":"Cheson BD, Greenberg PL, Bennett JM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-425.","DOI":"10.1182\/blood-2005-10-4149"},{"key":"73703","doi-asserted-by":"crossref","unstructured":"Cheson BD, Bennett JM, Kopecky KJ. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21(24):4642-4649.","DOI":"10.1200\/JCO.2003.04.036"},{"key":"73704","doi-asserted-by":"crossref","unstructured":"Oh ST, Verstovsek S, Gotlib J. bone marrow fibrosis changes do not correlate with efficacy outcomes in myelofibrosis: analysis of more than 300 JAK inhibitor-na\u00efve patients treated with momelotinib or ruxolitinib. Blood. 2022; 140(Supplement 1):821-823.","DOI":"10.1182\/blood-2022-160409"},{"key":"73705","doi-asserted-by":"crossref","unstructured":"Geyer H, Mesa RA. Approach to MPN symptom assessment. Curr Hematol Malig Rep. 2017; 12(5):381-388.","DOI":"10.1007\/s11899-017-0399-5"},{"key":"73706","doi-asserted-by":"crossref","unstructured":"Lancet JE, Uy GL, Newell LF. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021; 8(7):e481-e491.","DOI":"10.1016\/S2352-3026(21)00134-4"},{"key":"73707","doi-asserted-by":"crossref","unstructured":"Ilyas R, McCullough K, Badar T. CPX-351 (VyxeosTM) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases. Blood Cancer J. 2023; 13(1):26.","DOI":"10.1038\/s41408-023-00800-2"},{"key":"73708","doi-asserted-by":"crossref","unstructured":"Burd A, Levine RL, Ruppert AS. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master trial. Nat Med. 2020; 26(12):1852-1858.","DOI":"10.1038\/s41591-020-1089-8"},{"key":"73709","doi-asserted-by":"crossref","unstructured":"Little RF, Othus M, Assouline S. Umbrella trial in myeloid malignancies: the Myelomatch national clinical trials network precision medicine initiative. Blood. 2022; 140(Supplement 1):9057-9060.","DOI":"10.1182\/blood-2022-169307"},{"key":"73710","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Verstovsek S, Mesa R. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 2022; 128(13):2420-2432.","DOI":"10.1002\/cncr.34205"},{"key":"73711","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Mead AJ, Somervaille TCP. Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. Blood. 2023; 142(Supplement 1):620.","DOI":"10.1182\/blood-2023-173509"},{"key":"73712","doi-asserted-by":"crossref","unstructured":"Rampal RK, Grosicki S, Chraniuk D. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the MANIFEST-2 randomized double-blind phase 3 study. Blood. 2023; 142(Supplement 1):628.","DOI":"10.1182\/blood-2023-179141"},{"key":"73713","doi-asserted-by":"crossref","unstructured":"Chen EC, Johnston H, Patel AA. Targeted therapy for MPNs: going beyond JAK inhibitors. Curr Hematol Malig Rep. 2023; 18(3):41-55.","DOI":"10.1007\/s11899-023-00690-y"},{"key":"73714","doi-asserted-by":"crossref","unstructured":"Marinaccio C, Suraneni P, Celik H. LKB1\/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms. Cancer Discov. 2021; 11(6):1398-1410.","DOI":"10.1158\/2159-8290.CD-20-1353"},{"key":"73715","doi-asserted-by":"crossref","unstructured":"Kong T, Laranjeira ABA, Yang K. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. Nat Cancer. 2023; 4(1):108-127.","DOI":"10.1038\/s43018-022-00486-8"},{"key":"73716","doi-asserted-by":"crossref","unstructured":"Saenz DT, Fiskus W, Manshouri T. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia. 2017; 31(3):678-687.","DOI":"10.1038\/leu.2016.260"},{"key":"73717","doi-asserted-by":"crossref","unstructured":"Fiskus W, Mill CP, Nabet B. Superior efficacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021; 11(5):98.","DOI":"10.1038\/s41408-021-00487-3"},{"key":"73718","doi-asserted-by":"crossref","unstructured":"Fiskus W, Manshouri T, Birdwell C. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022; 12(1):23.","DOI":"10.1038\/s41408-022-00618-4"},{"key":"73719","doi-asserted-by":"crossref","unstructured":"Li B, An W, Wang H. BMP2\/SMAD pathway activation in JAK2\/p53-mutant megakaryocyte\/erythroid progenitors promotes leukemic transformation. Blood. 2022; 139(25):3630-3646.","DOI":"10.1182\/blood.2021014465"},{"key":"73720","doi-asserted-by":"crossref","unstructured":"Systchenko T, Chomel J-C, Gallego-Hernanz P. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms. Br J Haematol. 2023; 202(2):284-288.","DOI":"10.1111\/bjh.18853"},{"key":"73721","doi-asserted-by":"crossref","unstructured":"Bar-Natan M, Mascarenhas J, Gerds AT. Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119. Blood. 2022; 140(Supplement 1):3988-3990.","DOI":"10.1182\/blood-2022-164678"},{"key":"73722","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Lasho TL, Rotunno G. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014; 28(9):1804-1810.","DOI":"10.1038\/leu.2014.76"},{"key":"73723","doi-asserted-by":"crossref","unstructured":"Tefferi A, Lasho TL, Guglielmelli P. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016; 1(1):21-30.","DOI":"10.1182\/bloodadvances.2016000216"},{"key":"73724","doi-asserted-by":"crossref","unstructured":"Salit RB, Deeg HJ. Transplant decisions in patients with myelofibrosis: should mutations be the judge?. Biol Blood Marrow Transplant. 2018; 24(4):649-658.","DOI":"10.1016\/j.bbmt.2017.10.037"},{"key":"73725","doi-asserted-by":"crossref","unstructured":"Tefferi A, Guglielmelli P, Lasho TL. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014; 28(7):1494-1500.","DOI":"10.1038\/leu.2014.57"},{"key":"73726","doi-asserted-by":"crossref","unstructured":"Tefferi A, Cervantes F, Mesa R. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122(8):1395-1398.","DOI":"10.1182\/blood-2013-03-488098"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283950\/77673","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283950\/78233","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11795\/77673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:31Z","timestamp":1794046051000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283950","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}